A search at the store earlier this year found illegal vapes, erectile dysfunction tablets, chewing tobacco and untaxed beer, ...
Cerebras is seeking to go public at a valuation of about $8 billion. There are several red flags why I won't invest in its ...
Pioneering Discussions at IISLD 2024: Advancing Treatment for PBC and Alpha-1 Antitrypsin Deficiency
This year's International Symposium on Liver Diseases (IISLD) 2024, held in the San Diego Convention Center, includes two key ...
In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...
Daryl Brown, who was prescribed the antidepressant Seroxat in childhood because of his Tourette’s syndrome and OCD, tells ...
We recently published an article titled Jim Cramer on Super Micro Computer and Other Stocks. In this article, we are going to ...
Biohaven has surged driven by promising data from its troriluzole trials for spinocerebellar ataxia and ongoing OCD studies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback